Joe O'COnnell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joe O'COnnell has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Fergus Shanahan
APC Microbiome Ireland, University College Cork, Cork, Ireland
11 shared publications - Aileen Houston
Cancer Research @ UCC, University College Cork, Ireland; Department of Medicine, University College Cork, Ireland
4 shared publications Kenneth Nally
Department of Medicine, University College Cork, Ireland
4 shared publicationsMichael W. Bennett
Department of Medicine, National University of Ireland, University Hospital, Cork, Ireland
4 shared publicationsGerald C. O'SUllivan
Department of Surgery, Mercy Hospital, National University of Ireland, Cork
3 shared publicationsJ. Kevin Collins
Department of Medicine, National University of Ireland, Cork, Ireland
2 shared publications
Latest Publications
- Open Access
- 1 January 2006
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 5 (1) , 5
Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data
J Carcinog, Official publication of Carcenogenesis Press
- 1 January 2006
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 5 (1) , 5
Open AccessFas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data
J Carcinog, Official publication of Carcenogenesis Press
- Open Access
- 30 September 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (7) , 1345-1351
Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression
Many cancers express Fas ligand (FasL/CD95L) in vivo, and can kill lymphoid cells by Fas-mediated apoptosis in vitro. However, overexpression of recombinant FasL in murine tumour allografts revealed a potential antitumour effect of FasL, via recruitment of neutrophils. Transforming growth factor-beta1 (TGF-beta1) could inhibit these neutrophil-stimulatory effects of FasL. In the present study, we sought to determine directly whether FasL contributes to immune privilege or tumour rejection in human colon cancers in vivo, and whether TGF-beta1 regulates FasL function. Serial tumour sections were immunostained for FasL and TGF-beta1. Neutrophils and tumour infiltrating lymphocytes (TILs) were detected by immunohistochemistry for lactoferrin and CD45, respectively. Apoptotic TIL were identified by dual staining for TUNEL/CD45. FasL expression by nests of tumour cells was associated with a mean four-fold depletion of TILs (range 1.8-33-fold, n=16, P<0.001), together with a two-fold increase in TIL apoptosis (range 1.6-2.5-fold, n=14, P<0.001), relative to FasL-negative nests within the same tumours. The overall level of neutrophils present in all tumours examined was low (mean 0.3%, n=16), with FasL expression by tumour nests associated with a mean two-fold decrease in neutrophils, irrespective of TGF-beta1 expression. Together, our results suggest that tumour-expressed FasL is inhibitory rather than stimulatory towards antitumour immune responses.
- 30 September 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (7) , 1345-1351
Open AccessFas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression
Many cancers express Fas ligand (FasL/CD95L) in vivo, and can kill lymphoid cells by Fas-mediated apoptosis in vitro. However, overexpression of recombinant FasL in murine tumour allografts revealed a potential antitumour effect of FasL, via recruitment of neutrophils. Transforming growth factor-beta1 (TGF-beta1) could inhibit these neutrophil-stimulatory effects of FasL. In the present study, we sought to determine directly whether FasL contributes to immune privilege or tumour rejection in human colon cancers in vivo, and whether TGF-beta1 regulates FasL function. Serial tumour sections were immunostained for FasL and TGF-beta1. Neutrophils and tumour infiltrating lymphocytes (TILs) were detected by immunohistochemistry for lactoferrin and CD45, respectively. Apoptotic TIL were identified by dual staining for TUNEL/CD45. FasL expression by nests of tumour cells was associated with a mean four-fold depletion of TILs (range 1.8-33-fold, n=16, P<0.001), together with a two-fold increase in TIL apoptosis (range 1.6-2.5-fold, n=14, P<0.001), relative to FasL-negative nests within the same tumours. The overall level of neutrophils present in all tumours examined was low (mean 0.3%, n=16), with FasL expression by tumour nests associated with a mean two-fold decrease in neutrophils, irrespective of TGF-beta1 expression. Together, our results suggest that tumour-expressed FasL is inhibitory rather than stimulatory towards antitumour immune responses.
- Open Access
- 6 August 2003
- Published by Wiley in International Journal of Cancer
- Vol. 107 (2) , 209-214
Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo
Expression of Fas ligand (FasL/CD95L) may help to maintain colon cancers in a state of immune privilege by inducing apoptosis of antitumor immune effector cells. Colon tumor-derived cell lines appear to be relatively insensitive to apoptosis mediated by their own or exogenous FasL in vitro, despite expression of cell surface Fas. In our present study, we sought to investigate if FasL upregulated in human colon cancers leads to any increase in apoptosis of the tumor cells in vivo. FasL and Fas receptor (APO-1/CD95) expression by tumor cells were detected immunohistochemically. Apoptotic tumor cell death was detected by immunohistochemistry for caspase-cleaved cytokeratin-18. FasL expression did not correlate with the extent of apoptosis of tumor cells. There was no significant local difference in the frequency of apoptosis of tumor cells between tumor nests that expressed FasL (mean = 2.4%) relative to those that did not (mean = 2.6%) (p = 0.625, n = 10; Wilcoxon signed rank). FasL expressed by the tumor cells appeared to be functional, since FasL expression in tumor nests correlated with diminished infiltration of tumor-infiltrating lymphocytes (TILs). TILs were detected using immunohistochemistry for CD45. Expression of FasL by tumor nests was associated with a mean 4-fold fewer TILs relative to FasL-negative nests (range 2.4–33-fold, n = 10, p < 0.003). Together, our results indicate that colon tumors are insensitive to FasL-mediated apoptosis in vivo.
- 6 August 2003
- Published by Wiley in International Journal of Cancer
- Vol. 107 (2) , 209-214
Open AccessFas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo
Expression of Fas ligand (FasL/CD95L) may help to maintain colon cancers in a state of immune privilege by inducing apoptosis of antitumor immune effector cells. Colon tumor-derived cell lines appear to be relatively insensitive to apoptosis mediated by their own or exogenous FasL in vitro, despite expression of cell surface Fas. In our present study, we sought to investigate if FasL upregulated in human colon cancers leads to any increase in apoptosis of the tumor cells in vivo. FasL and Fas receptor (APO-1/CD95) expression by tumor cells were detected immunohistochemically. Apoptotic tumor cell death was detected by immunohistochemistry for caspase-cleaved cytokeratin-18. FasL expression did not correlate with the extent of apoptosis of tumor cells. There was no significant local difference in the frequency of apoptosis of tumor cells between tumor nests that expressed FasL (mean = 2.4%) relative to those that did not (mean = 2.6%) (p = 0.625, n = 10; Wilcoxon signed rank). FasL expressed by the tumor cells appeared to be functional, since FasL expression in tumor nests correlated with diminished infiltration of tumor-infiltrating lymphocytes (TILs). TILs were detected using immunohistochemistry for CD45. Expression of FasL by tumor nests was associated with a mean 4-fold fewer TILs relative to FasL-negative nests (range 2.4–33-fold, n = 10, p < 0.003). Together, our results indicate that colon tumors are insensitive to FasL-mediated apoptosis in vivo.
- 27 June 2003
- Published by Wiley in Journal of Cellular Physiology
- Vol. 197 (1) , 30-41
Neurokinin‐1 receptor (NK‐1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P
We have previously shown that the receptor for substance P (SP), neurokinin‐1 receptor (NK‐1R), is a marker of human mucosal but not peripheral mononuclear cells. In the present study, we investigate NK‐1R expression in the human colonic mucosa in vivo, particularly in the epithelial cells. We investigate the influence of proinflammatory Th1 cytokines and SP on expression and function of NK‐1R in colonic epithelial cells in vitro. Using in situ hybridization to detect NK‐1R mRNA, and immunohistochemistry to detect NK‐1R protein, colonic epithelial cells were found to express NK‐1R in vivo. In contrast, colon epithelial cell lines (Caco‐2, HT29, SW620, T84) were negative for NK‐1R mRNA and protein. However, stimulation with a proinflammatory cytokine cocktail containing IFN‐γ, TNF‐α, and IL‐1β, caused induction of NK‐1R expression. Expression of NK‐1R in human colonic epithelial cells in vivo may therefore reflect cytokine conditioning by the mucosal microenvironment. SP did not alter ion transport in monolayers of cytokine‐treated T84 cells. While SP stimulated epithelial ion transport in colonic mucosae ex vivo, this was not a direct effect of SP on the epithelial cells, and appeared to be neurally mediated. However, SP (10−10–10−8 M) elicited a dose‐dependent proliferative effect on cytokine‐stimulated, but not unstimulated, SW620 cells. Proliferation of the epithelial cells in response to SP was mediated specifically via cytokine‐induced NK‐1R, since an NK‐1R‐specific antagonist (Spantide 1) completely blocked SP‐mediated proliferation in the cytokine‐treated cells. Our results therefore demonstrate that proinflammatory cytokines induce expression of NK‐1R in human colonic epithelial cell lines, and that SP induces proliferation of the epithelial cells via cytokine‐induced NK‐1R. J. Cell. Physiol. 197: 30–41, 2003
- 27 June 2003
- Published by Wiley in Journal of Cellular Physiology
- Vol. 197 (1) , 30-41
Neurokinin‐1 receptor (NK‐1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P
We have previously shown that the receptor for substance P (SP), neurokinin‐1 receptor (NK‐1R), is a marker of human mucosal but not peripheral mononuclear cells. In the present study, we investigate NK‐1R expression in the human colonic mucosa in vivo, particularly in the epithelial cells. We investigate the influence of proinflammatory Th1 cytokines and SP on expression and function of NK‐1R in colonic epithelial cells in vitro. Using in situ hybridization to detect NK‐1R mRNA, and immunohistochemistry to detect NK‐1R protein, colonic epithelial cells were found to express NK‐1R in vivo. In contrast, colon epithelial cell lines (Caco‐2, HT29, SW620, T84) were negative for NK‐1R mRNA and protein. However, stimulation with a proinflammatory cytokine cocktail containing IFN‐γ, TNF‐α, and IL‐1β, caused induction of NK‐1R expression. Expression of NK‐1R in human colonic epithelial cells in vivo may therefore reflect cytokine conditioning by the mucosal microenvironment. SP did not alter ion transport in monolayers of cytokine‐treated T84 cells. While SP stimulated epithelial ion transport in colonic mucosae ex vivo, this was not a direct effect of SP on the epithelial cells, and appeared to be neurally mediated. However, SP (10−10–10−8 M) elicited a dose‐dependent proliferative effect on cytokine‐stimulated, but not unstimulated, SW620 cells. Proliferation of the epithelial cells in response to SP was mediated specifically via cytokine‐induced NK‐1R, since an NK‐1R‐specific antagonist (Spantide 1) completely blocked SP‐mediated proliferation in the cytokine‐treated cells. Our results therefore demonstrate that proinflammatory cytokines induce expression of NK‐1R in human colonic epithelial cell lines, and that SP induces proliferation of the epithelial cells via cytokine‐induced NK‐1R. J. Cell. Physiol. 197: 30–41, 2003
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A158
Fas activates the AP-1 transcription factor via the ERK1/2 and p38 MAPK pathways
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A158
Fas activates the AP-1 transcription factor via the ERK1/2 and p38 MAPK pathways
- 1 November 2002
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 973 (1) , 555-558
Type I Insulin-like Growth Factor Receptor Expression on Colorectal Adenocarcinoma Cell Lines Is Decreased in Response to the Chemopreventive AgentN-Acetyl-l-Cysteine
Increased expression of the type I insulin‐like growth factor receptor (IGF‐1R) is associated with colon cancer, while the antioxidant N‐acetyl‐l‐cysteine (NAC) is known to suppress colonic proliferation. We demonstrate that NAC down‐regulates the expression of IGF‐1R on three colorectal adenocarcinoma cell lines (HT29, SW480, and LoVo). NAC also abrogates the proliferative effect of IGF‐I on HT29 cells. This indicates a novel mechanism for the therapeutic effects of NAC.
- 1 November 2002
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 973 (1) , 555-558
Type I Insulin-like Growth Factor Receptor Expression on Colorectal Adenocarcinoma Cell Lines Is Decreased in Response to the Chemopreventive AgentN-Acetyl-l-Cysteine
Increased expression of the type I insulin‐like growth factor receptor (IGF‐1R) is associated with colon cancer, while the antioxidant N‐acetyl‐l‐cysteine (NAC) is known to suppress colonic proliferation. We demonstrate that NAC down‐regulates the expression of IGF‐1R on three colorectal adenocarcinoma cell lines (HT29, SW480, and LoVo). NAC also abrogates the proliferative effect of IGF‐I on HT29 cells. This indicates a novel mechanism for the therapeutic effects of NAC.
- 25 March 2002
- Published by Wiley in Immunology
- Vol. 105 (3) , 263-266
Fas ligand and the fate of antitumour cytotoxic T lymphocytes
- 25 March 2002
- Published by Wiley in Immunology
- Vol. 105 (3) , 263-266
Fas ligand and the fate of antitumour cytotoxic T lymphocytes
- 12 March 2001
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 3 (31) , 1-18
Role of Fas–FasL in inflammatory diseases
Fas ligand (FasL) induces programmed cell death, or ‘apoptosis’, in cells expressing its cognate receptor, Fas (CD95/APO-1). There is evidence that FasL precludes inflammatory reactions from sites of ‘immune privilege’ by triggering Fas-mediated apoptosis of infiltrating pro-inflammatory cells. The ability of FasL to impair immune responses is being pursued as a possible means of protecting tissue transplants from immunological rejection, and therapeutic promise has been reported in some experiments. However, FasL is becoming an enigmatic molecule, exhibiting pro-inflammatory activity independently of its ability to mediate immune downregulation. FasL can recruit and activate neutrophils and macrophages in some experimental situations. Triggering of Fas in some cell types has been shown to upregulate expression of certain pro-inflammatory cytokines and chemokines, providing an unexpected link between apoptosis and inflammation. FasL appears to contribute to the destruction of Fas-sensitive end-organ cells during inflammation. This appears to occur in two ways: (1) direct killing by cytotoxic immune effector cells expressing FasL; or (2) autocrine cell suicide of end-organ cells that upregulate their own FasL in the inflammatory context. Depending on the condition, or the site of inflammation, either or both mechanisms may occur. Prevention of Fas-mediated end-organ apoptosis and enhancement of Fas-mediated apoptosis of inflammatory cells are emerging as potential anti-inflammatory therapeutic goals.
- 12 March 2001
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 3 (31) , 1-18
Role of Fas–FasL in inflammatory diseases
Fas ligand (FasL) induces programmed cell death, or ‘apoptosis’, in cells expressing its cognate receptor, Fas (CD95/APO-1). There is evidence that FasL precludes inflammatory reactions from sites of ‘immune privilege’ by triggering Fas-mediated apoptosis of infiltrating pro-inflammatory cells. The ability of FasL to impair immune responses is being pursued as a possible means of protecting tissue transplants from immunological rejection, and therapeutic promise has been reported in some experiments. However, FasL is becoming an enigmatic molecule, exhibiting pro-inflammatory activity independently of its ability to mediate immune downregulation. FasL can recruit and activate neutrophils and macrophages in some experimental situations. Triggering of Fas in some cell types has been shown to upregulate expression of certain pro-inflammatory cytokines and chemokines, providing an unexpected link between apoptosis and inflammation. FasL appears to contribute to the destruction of Fas-sensitive end-organ cells during inflammation. This appears to occur in two ways: (1) direct killing by cytotoxic immune effector cells expressing FasL; or (2) autocrine cell suicide of end-organ cells that upregulate their own FasL in the inflammatory context. Depending on the condition, or the site of inflammation, either or both mechanisms may occur. Prevention of Fas-mediated end-organ apoptosis and enhancement of Fas-mediated apoptosis of inflammatory cells are emerging as potential anti-inflammatory therapeutic goals.
- 1 March 2001
- Published by Springer Nature in Nature Medicine
- Vol. 7 (3) , 271-274
Immune privilege or inflammation? Insights into the Fas ligand enigma
Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.
- 1 March 2001
- Published by Springer Nature in Nature Medicine
- Vol. 7 (3) , 271-274
Immune privilege or inflammation? Insights into the Fas ligand enigma
Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.
- 25 October 2000
- Published by Wiley in Journal of Cellular Physiology
- Vol. 185 (3) , 331-338
Interferon-? sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis
Homeostasis in the colonic epithelium is achieved by a continuous cycle of proliferation and apoptosis, in which imbalances are associated with disease. Inflammatory bowel disease (IBD) and colon cancer are associated with either excessive or insufficient apoptosis of colonic epithelial cells, respectively. By using two colonic epithelial cell lines, HT29 and SW620, we investigated how the epithelial cell's sensitivity to apoptosis was regulated by the proinflammatory cytokine interferon-γ (IFN-γ). We found that IFN-γ sensitized HT29 cells, and to a lesser extent SW620, to diverse inducers of apoptosis of physiologic or therapeutic relevance to the colon. These apoptosis inducers included Fas (CD95/APO-1) ligand (FasL), short-chain fatty acids, and chemotherapeutic drugs. The extent of IFN-γ-mediated apoptosis sensitization in these two cell lines correlated well with the degree of IFN-γ-mediated upregulation of the proapoptotic protease caspase-1. Although IFN-γ alone effectively sensitized HT29 cells to apoptosis, inclusion of the protein synthesis inhibitor cyclohexamide (CHX) during apoptotic challenge was necessary for maximal sensitization of SW620. The requirement of CHX to sensitize SW620 cells to apoptosis implies a need to inhibit translation of antiapoptotic proteins absent from HT29. In particular, the antiapoptotic protein Bcl-2 was strongly expressed in SW620 cells but absent from HT29. Our results indicate that IFN-γ increases the sensitivity of colonic epithelial cells to diverse apoptotic stimuli in concert, via upregulation of caspase-1. Our findings implicate caspase-1 and Bcl-2 as important central points of control determining the general sensitivity of colonic epithelial cells to apoptosis. J. Cell. Physiol. 185:331–338, 2000.
- 25 October 2000
- Published by Wiley in Journal of Cellular Physiology
- Vol. 185 (3) , 331-338
Interferon-? sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis
Homeostasis in the colonic epithelium is achieved by a continuous cycle of proliferation and apoptosis, in which imbalances are associated with disease. Inflammatory bowel disease (IBD) and colon cancer are associated with either excessive or insufficient apoptosis of colonic epithelial cells, respectively. By using two colonic epithelial cell lines, HT29 and SW620, we investigated how the epithelial cell's sensitivity to apoptosis was regulated by the proinflammatory cytokine interferon-γ (IFN-γ). We found that IFN-γ sensitized HT29 cells, and to a lesser extent SW620, to diverse inducers of apoptosis of physiologic or therapeutic relevance to the colon. These apoptosis inducers included Fas (CD95/APO-1) ligand (FasL), short-chain fatty acids, and chemotherapeutic drugs. The extent of IFN-γ-mediated apoptosis sensitization in these two cell lines correlated well with the degree of IFN-γ-mediated upregulation of the proapoptotic protease caspase-1. Although IFN-γ alone effectively sensitized HT29 cells to apoptosis, inclusion of the protein synthesis inhibitor cyclohexamide (CHX) during apoptotic challenge was necessary for maximal sensitization of SW620. The requirement of CHX to sensitize SW620 cells to apoptosis implies a need to inhibit translation of antiapoptotic proteins absent from HT29. In particular, the antiapoptotic protein Bcl-2 was strongly expressed in SW620 cells but absent from HT29. Our results indicate that IFN-γ increases the sensitivity of colonic epithelial cells to diverse apoptotic stimuli in concert, via upregulation of caspase-1. Our findings implicate caspase-1 and Bcl-2 as important central points of control determining the general sensitivity of colonic epithelial cells to apoptosis. J. Cell. Physiol. 185:331–338, 2000.